Considerations for CTO Stenting
Characteristics for Stenting a CTO LesionHear his perspective
The SYNERGY Stent is indicated for treatment of patients presenting with coronary artery total occlusion lesions and has a labeled overexpansion of up to 5.75mm allowing the physician to customize the stent to the appropriate vessel size.
SYNERGY Stent System DFU
The SYNERGY Stent’s customized architecture offers exceptional strength and conformability.
Radial Strength: Amount of radial force required to reduce the diameter of a deployed stent by 15%
Conformability: The amount of torque required to bend the stent to a specific curvature
The SYNERGY Stent’s bioabsorbable polymer and abluminal coating are designed for early healing as the polymer is gone when no longer needed, shortly after completion of drug elution at 3 months.
Wilson, G.J., et al. Catheter Cardiovasc Interv. 2015.
Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.
Boston Scientific is committed to supporting studies evaluating the SYNERGY Stent in patient populations that interventional Cardiologists see in their everyday practice, including CTO stenting.